Term
| Abatacept (Orencia). inhibits CD80/86 on APC to prevent T cell stimulation |
|
Definition
| T-Cell costimulator modulator. IV 100-1000 Weeks 0,2,4, and then monthly; SC 125 mg weely. |
|
|
Term
| Adalimumab (Humira). Human monoclonal antibody TNF |
|
Definition
| TNF-alpha inhibitor. SC 40 mg every 14d but may be every week on patients not taking methotrexate. |
|
|
Term
|
Definition
| IL-1 Receptor antagonist. 100 mg SC. Daily. |
|
|
Term
| Certolizumab (Cimzia). Pegylated Fab fragment of humanized anti-TNF monoclonal antibody |
|
Definition
| TNF-alpha inhibitor. 400 mg SC weeks 0,2, and 4; followed by 200 mg SC every 2 weeks |
|
|
Term
| Etanercept (Enbrel)Dimeric fusion protein human p75 TNF receptor linked to an Fc fragment of human IgG |
|
Definition
| TNF-alpha inhibitor. 50 mg SC weekly; 25 mg SC twice weekly. |
|
|
Term
| Golimumab (Simponi). human anti-TNF IgG monoclonal antibody binding to soluable and transmembrane TNF. |
|
Definition
| TNF-alpha inhibitor. 50 mg SC monthly with methotrexate. |
|
|
Term
| Infliximab (Remicade). Chimeric antibody Murine and Human IgG |
|
Definition
| TNF-alpha inhibitor. 3 mg/kg IV infusion on weeks 0, 2, and 6; then every 8 weeks with methotrexate (can be done every 4 weeks to nonresponders) |
|
|
Term
|
Definition
| Anti-CD20. 1000 mg IV. Days 1 and 15 may retreat every 24 weeks (no sooner than 16 weeks). Combine with methotrexate. |
|
|
Term
|
Definition
| IL-6 receptor antagonist. IV 4 mg/kg; may increase to 8 mg/kg and is given every four weeks. SC 162 QW/QOW (<100kg/>100kg). |
|
|
Term
|
Definition
| Janus Kinase enzyme inhibitor. 5 mg PO QD. |
|
|
